PharmExec

FDA Approves Lerochol for Adults with Elevated LDL Cholesterol

FDA has announced the approval of LIB Therapeutics’ Lerochol (lerodalcibep-liga) for subcutaneous (SC) use as an adjunct to ...
eLife

Global molecular landscape of early MASLD progression in obesity

The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...
Le Lézard

U.S. Food and Drug Administration Approves LIB Therapeutics' LEROCHOLtm (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their cholesterol goals, today announced the U.S. Food and Drug ...

Understanding haemoglobin levels: How low is too low, red flags to watch out for

When the body lacks iron, it can impact haemoglobin levels. And when you have low haemoglobin, it affects your health ...
eLife

Single molecule counting detects low-copy glycine receptors in hippocampal and striatal synapses

The study presents convincing quantitative evidence, supported by appropriate negative controls, for the presence of low-abundance glycine receptors (GlyRs) within inhibitory synapses in telencephalic ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or ...